Senzime publishes annual and sustainability report for 2022

Uppsala, April 25, 2023. Senzime AB (publ) announces today that the company’s annual and sustainability report for 2022 is published and available at the website senzime.com.

"We significantly strengthened our positioning on the market in 2022, and I anticipate 2023 being a year when we will continue to experience high growth driven by our commercial strategy, supported by the clinical guidelines,” said Pia Renaudin, CEO of Senzime. “We have also managed several projects to reduce our climate footprint and increased our engagement in the sustainability segment.”

For further information, please contact:

Pia Renaudin, CEO of Senzime AB 
Phone: +46 (0) 70 813 34 17, e-mail: [email protected]
 
Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: [email protected]

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

This information is information that Senzime is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-04-25 09:15 CEST.

Report
en sv de